- In a retrospective study, almost half of patients receiving apremilast achieved ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) at 12 months, although gastrointestinal problems were common.
Why this matters
- Little is known about the real-world effectiveness and safety of apremilast.
- At 1 year, 49.7% of patients achieved PASI 75 and 26.5% achieved PASI 90.
- Mean physician global assessment score for palmoplantar psoriasis decreased from 4.2 at baseline to 1.3 at week 52.
- 1-year drug survival was 54.9%.
- The most common reasons for treatment discontinuation were loss of efficacy (23.9%) and adverse events (AEs; 15.9%).
- 47% of patients experienced ≥1 AE; the most common were gastrointestinal problems and asthenia.
- 292 patients with plaque psoriasis and 85 patients with palmoplantar psoriasis who were treated with apremilast were included.
- Funding: None.